These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16446485

  • 1. Controlled-release opioids and alcohol.
    Darke AC.
    CMAJ; 2006 Jan 31; 174(3):352. PubMed ID: 16446485
    [No Abstract] [Full Text] [Related]

  • 2. Alcohol-associated rapid release of a long-acting opioid.
    Murray S, Wooltorton E.
    CMAJ; 2005 Sep 27; 173(7):756. PubMed ID: 16150957
    [No Abstract] [Full Text] [Related]

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Sep 27; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 4. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May 11; 148(19):47. PubMed ID: 16736708
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral hydromorphone extended-release.
    Guay DR.
    Consult Pharm; 2010 Dec 11; 25(12):816-28. PubMed ID: 21172762
    [Abstract] [Full Text] [Related]

  • 7. The metamorphosis of hydromorphone.
    Reisfield GM, Wilson GR.
    J Opioid Manag; 2005 Dec 11; 1(3):139-45. PubMed ID: 17315417
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
    Vashi V, Harris S, El-Tahtawy A, Wu D, Cipriano A.
    J Clin Pharmacol; 2005 May 11; 45(5):547-54. PubMed ID: 15831778
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
    Carter NJ, Keating GM.
    CNS Drugs; 2010 Apr 11; 24(4):337-61. PubMed ID: 20297858
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, Standop J, Kloecker N, Nadstawek J.
    Eur J Pain; 2009 Aug 11; 13(7):737-43. PubMed ID: 18977159
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Alcohol and drug interactions].
    Duquet N.
    J Pharm Belg; 2008 Dec 11; 63(4):110-5. PubMed ID: 19320135
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment.
    Durnin C, Hind ID, Wickens MM, Yates DB, Molz KH.
    Proc West Pharmacol Soc; 2001 Dec 11; 44():81-2. PubMed ID: 11794004
    [No Abstract] [Full Text] [Related]

  • 20. Auditory symptoms as an unrecognized manifestation of opioid toxicity: two case reports.
    Cran A, Kiely F, O'Brien T.
    J Pain Palliat Care Pharmacother; 2014 Dec 11; 28(4):378-81. PubMed ID: 25299483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.